|
Name |
Bipolacochlioquinone A
|
Molecular Formula | C32H48O7 | |
IUPAC Name* |
[2-[6-(2-hydroxypropan-2-yl)-3,11,14-trimethyl-7,12,18,20-tetraoxapentacyclo[11.7.1.02,11.03,8.017,21]henicosa-13,15,17(21)-trien-15-yl]-4-methylhexan-3-yl]acetate
|
|
SMILES |
CCC(C)C(OC(C)=O)C(C)c1cc2c3c(c1C)OC1(C)CCC4OC(C(C)(C)O)CCC4(C)C1C3OCO2
|
|
InChI |
InChI=1S/C32H48O7/c1-10-17(2)26(37-20(5)33)18(3)21-15-22-25-27(19(21)4)39-32(9)14-12-24-31(8,29(32)28(25)36-16-35-22)13-11-23(38-24)30(6,7)34/h15,17-18,23-24,26,28-29,34H,10-14,16H2,1-9H3/t17-,18-,23+,24+,26+,28+,29+,31-,32+/m0/s1
|
|
InChIKey |
GNBNFERUAIVQSQ-ZROGDPERSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 544.73 | ALogp: | 6.4 |
HBD: | 1 | HBA: | 7 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 83.5 | Aromatic Rings: | 5 |
Heavy Atoms: | 39 | QED Weighted: | 0.418 |
Caco-2 Permeability: | -4.937 | MDCK Permeability: | 0.00001260 |
Pgp-inhibitor: | 0.998 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.014 |
30% Bioavailability (F30%): | 0.661 |
Blood-Brain-Barrier Penetration (BBB): | 0.26 | Plasma Protein Binding (PPB): | 98.68% |
Volume Distribution (VD): | 1.56 | Fu: | 2.46% |
CYP1A2-inhibitor: | 0.008 | CYP1A2-substrate: | 0.745 |
CYP2C19-inhibitor: | 0.049 | CYP2C19-substrate: | 0.951 |
CYP2C9-inhibitor: | 0.092 | CYP2C9-substrate: | 0.072 |
CYP2D6-inhibitor: | 0.033 | CYP2D6-substrate: | 0.129 |
CYP3A4-inhibitor: | 0.45 | CYP3A4-substrate: | 0.888 |
Clearance (CL): | 6.828 | Half-life (T1/2): | 0.028 |
hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.602 |
Drug-inuced Liver Injury (DILI): | 0.282 | AMES Toxicity: | 0.061 |
Rat Oral Acute Toxicity: | 0.803 | Maximum Recommended Daily Dose: | 0.751 |
Skin Sensitization: | 0.035 | Carcinogencity: | 0.032 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.012 |
Respiratory Toxicity: | 0.693 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004571 | 0.636 | D0Y7LD | 0.235 | ||||
ENC004251 | 0.617 | D0W5LS | 0.229 | ||||
ENC000943 | 0.605 | D0L7AS | 0.216 | ||||
ENC004573 | 0.504 | D01CKY | 0.215 | ||||
ENC001862 | 0.479 | D02CJX | 0.215 | ||||
ENC003006 | 0.474 | D0X7XG | 0.213 | ||||
ENC002674 | 0.474 | D0T7ZQ | 0.213 | ||||
ENC005794 | 0.465 | D0W2EK | 0.212 | ||||
ENC002182 | 0.454 | D04GJN | 0.208 | ||||
ENC003489 | 0.454 | D08IWD | 0.208 |